Immunocore Holdings plc (NASDAQ:IMCR) Given Average Recommendation of “Moderate Buy” by Analysts

Immunocore Holdings plc (NASDAQ:IMCR) has received an average rating of “Moderate Buy” from the thirteen brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $69.18.

A number of brokerages have recently issued reports on IMCR. Oppenheimer reaffirmed an “outperform” rating and set a $89.00 price target (up previously from $87.00) on shares of Immunocore in a report on Friday, August 9th. Needham & Company LLC dropped their price target on shares of Immunocore from $78.00 to $71.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Immunocore in a report on Thursday, October 24th. Mizuho downgraded shares of Immunocore from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $72.00 to $38.00 in a report on Monday, November 11th. Finally, UBS Group started coverage on shares of Immunocore in a report on Thursday, October 24th. They set a “sell” rating and a $24.00 price target on the stock.

Immunocore Stock Down 3.2 %

NASDAQ:IMCR opened at $31.59 on Friday. The firm has a market cap of $1.58 billion, a P/E ratio of -33.25 and a beta of 0.72. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. Immunocore has a fifty-two week low of $29.72 and a fifty-two week high of $76.98. The firm has a 50-day simple moving average of $32.44 and a two-hundred day simple moving average of $38.66.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.50. The business had revenue of $80.25 million during the quarter, compared to analyst estimates of $78.94 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. Immunocore’s revenue was up 23.7% compared to the same quarter last year. During the same period last year, the business earned ($0.59) EPS. Analysts predict that Immunocore will post -0.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immunocore

Large investors have recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC lifted its holdings in Immunocore by 40.4% during the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock valued at $158,000 after purchasing an additional 1,461 shares in the last quarter. Connective Portfolio Management LLC purchased a new position in Immunocore during the third quarter valued at approximately $218,000. China Universal Asset Management Co. Ltd. lifted its holdings in Immunocore by 69.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock valued at $231,000 after purchasing an additional 3,053 shares in the last quarter. DNB Asset Management AS raised its position in shares of Immunocore by 35.0% during the second quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock valued at $244,000 after buying an additional 1,868 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Immunocore during the second quarter valued at approximately $303,000. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.